Current management and recommendations on hepatitis B therapy in HIV-coinfected patients

Hepatology International

Volumn 7, Issue 2, 2013, Pages 437-442

  Piroth, Lionel ^a   Mahy, Sophie ^a   Pol, Stanislas ^b   Carrat, Fabrice ^c   Sene, Damien ^d,e   Etienne, Manuel ^f   Lascoux Combe, Caroline ^g   Simon, Anne ^d   Schmit, Jean Luc ^h   Cacoub, Patrice ^d,e  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b Institut Cochin   (France)

^c INSERM   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f ROUEN UNIVERSITY HOSPITAL   (France)

^g Section of Radiology   (France)

^h AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Guidelines; HBV; HIV; Management

Indexed keywords

ANTIVIRUS AGENT; VIRUS DNA;

ADULT; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PATIENT ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84879842297     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-011-9292-9     Document Type: Review

References (17)

1. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005;42:615-624
2. Larsen C, Pialoux G, Salmon D, et al. Prévalence des coinfections par les virus des hépatites B et C dans la population VIH+, France, juin 2004. BEH 2005;23:109-112
3. Piroth L, Pol S, Lacombe K, et al. Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study. J Hepatol 2010;53:1006-1012
4. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242
5. McMahon BJ. Selecting appropriate management strategies for chronic hepatitis B: who to treat. Am J Gastroenterol 2006;101:S7-S12
6. Thio C, Seaberg E, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-1926
7. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006;44:S65-S70
8. Hoffmann CJ, Seaberg EC, Young S, et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 2009;23:1881-1889
9. Bonacini M, Louie S, Bzowej N, Wohl A. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004;18(15):2039-2045
10. Rockstroh JK. Influence of viral hepatitis on HIV infection. J Hepatol 2006;44:S25-S27
11. Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 2003;4:241-249
12. Law WP, Duncombe CJ, Mahanontharit A, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004;18:1169-1177
13. Sheng W, Chen M, Hsieh S, et al. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis 2004;38:1471-1477
14. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 2006;44:S132-S139
15. Carr A, Cooper D. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997;349:995-996
16. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman K. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999;28:1032-1035
17. Lacombe K, Boyd A, Gozlan J, Lavocat F, Girard PM, Zoulim F. Drug-resistant and immune-escape HBV mutants in HIV-infected hosts. Antivir Ther 2010;15:493-497